Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

ombination with other cancer therapies and in a number of cancer types are underway or planned.

About Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit Pharmion's website at http://www.pharmion.com.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at http://www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements about the status of the FDA review process. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achie
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced sales ... compared to sales of $2,202,000 for the prior year period, ... has also shown growth over the preceding quarter,s sales, continuing ... fiscal year. Markets that experienced sales increases over the prior ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... ANN ARBOR, Mich., Oct. 12 Incept BioSystems, Inc. ... technology developed at the University of Michigan, announced today ... of its proprietary, SMART Start ™ Embryo Culture ... to the U.S. Food & Drug Administration ("FDA").  A ...
... with disabilities, their families, caregivers, seniors, wounded veterans and healthcare ... 15, through Sunday, October 17, 2010 at the Cobb Galleria ... Friday 11 am to 5 pm, Saturday 10 am to ... Abilities Expo has put together an impressive line-up of ...
Cached Medicine Technology:Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA 2Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA 3People With Disabilities Experience Their Possibilities at Abilities Expo in Atlanta, Georgia 2People With Disabilities Experience Their Possibilities at Abilities Expo in Atlanta, Georgia 3
(Date:7/11/2014)... July 11, 2014 The report ... Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, Preventive ... Global Trends & Forecasts to 2019 ” defines ... analysis and forecasting of the market value of ... the driving and restraining factors for the global ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Biostimulants are ... growth in turf and ornamentals. These also help turf ... improve length of roots. Turf, ornamentals, and flowers appear ... Therefore, this usage has increased from the last few ... turf and ornamentals is Europe, with around 40% share ...
(Date:7/11/2014)... and overweight firefighters are not receiving weight management ... new research from The University of Texas Health ... state that health care professionals (HCPs) should advise ... weight. Firefighters have high rates of obesity, and ... deaths in firefighters. This study assessed the association ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... Riverside Health System became the first provider of ... late 2012 and now, in partnership with Williamsburg Landing, will ... Williamsburg and Newport News region. , Also known as life ... independent older adults who wish to remain in their homes ... continuing care services as well as control over the cost ...
Breaking Medicine News(10 mins):Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... sisters can be tough work, as any youngest child will tell ... of North Carolina at Chapel Hill shows that when it comes ... first born or rather, first laid siblings as well. ... ONE, runs somewhat counter to common wisdom, which holds that baby ...
... Angeles, March 12 --Combined positron emission tomography (PET) and ... more effective method to evaluate response to radiation therapy, ... study by researchers at the University of Southern California ... be published in the March issue of the journal ...
... Partnerships, MHA Keystone and other initiatives are featured, ... health care,professionals provide an inside look at how ... Shield of Michigan are,saving lives, improving patient care ... from the Blues., "These partnerships demonstrate the ...
... Interim Results from National Chronic Disease ... ... participants in the Diabetes Ten City Challenge (DTCC) improved across,all ... of,the program, the American Pharmacists Association (APhA) Foundation,announced today., ...
... Omnicell,Inc. (Nasdaq: OMCL ), a leading provider of ... has completed its $40.0,million program to repurchase shares of ... at an average price of $18.75., About Omnicell, ... leading provider of systems and,software solutions targeting patient safety ...
... ARAY ), a global leader in the field of ... American Medical,Devices Product of the Year award, from global ... Radiosurgery System., The Frost & Sullivan Award for ... company that has demonstrated excellence in new product,development and ...
Cached Medicine News:Health News:Early bird doesn't always get worm, UNC researcher finds 2Health News:USC researchers find benefit for lymphoma patients in combined PET-CT scanning 2Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 2Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 3Health News:Partnerships Report Highlights How Blue Cross Blue Shield of Michigan, Physicians and Hospitals Are Working to Save Lives, Improve Care, Reduce Costs 4Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4Health News:Omnicell Announces Completion of Its Common Stock Repurchase Plan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 3